Menu

Dr. Linda Garland is a thoracic medical oncologist and translational researcher with expertise in mesothelioma. She currently serves as the Director of the Clinical Lung Cancer Program and Director of Clinical Research in Thoracic Oncology at the University of Arizona Cancer Center. Dr. Garland also works as a professor of medicine, specifically on the clinical-scholar track. She previously served for 10 years on the University of Arizona Institutional Review Board. Today, Dr. Garland serves as chair of the University of Arizona Cancer Center Scientific Review Committee.

Dr. Garland has built her career around searching for promising new ways to fight for cancer. Experimental therapeutics is the main focus of her research, particularly related to malignant diseases of the chest. She has developed and led translational clinical trials for novel targeted agents in advanced mesothelioma, as well as lung cancer. Her studies have investigated the efficacy of chemotherapy and focused on developing novel cancer therapies and biomarkers for earlier detection.

Main Specialty: Thoracic Medical Oncology

Other Interests & Specialties: Oncology, hematologic oncology, lung cancer, non-small cell lung cancer, parathyroid cancer, small cell lung cancer, head and neck cancer, squamous cell carcinoma, thyroid cancer and mesothelioma.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Medical Oncology, American Board of Internal Medicine Certification in Hematology, Chair of the University of Arizona Cancer Center Scientific Review Committee, member of The American College of Chest Physicians Task Force on Women and Girls, Tobacco, & Lung Cancer

Education & Experience:

  • Medical Degree from University of Texas Health Science Center
  • Residency for Internal Medicine at the University of South Florida College of Medicine
  • Fellowship for Hematology/Oncology at H. Lee Moffitt Cancer Center

Publications:
Phase II Study of mTOR Inhibitor Everolimus (RAD001) in Advanced Malignant Pleural Mesothelioma (MPM)Journal of Thoracic Oncology. February 15;10(2):387–391. doi: 10.1097/JTO.0000000000000360

Is There a Role for Cancer-Directed Surgery in Early-Stage Sarcomatoid or Biphasic Mesothelioma? The Annals of Thoracic Surgery. January 2019; 107(1):194 – 201. doi: 10.1016/j.athoracsur.2018.07.081

A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteriaJournal of Thoracic Oncology. March 2011;6(3):598–601. doi: 10.1097/JTO.0b013e318208c83d

Individualizing mesothelioma treatment: small steps into a brighter futureClinical Lung Cancer. November 2010;11(6):371-3. doi: 10.3816/CLC.2010.n.048

Mesothelioma Clinical Trials by Linda L. Garland

Dr. Linda L. Garland is associated with the following clinical trials:

S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: December 27, 2017

Status: Completed

Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung


Conditions: Mesothelioma, Lung Neoplasms

Last Updated: January 23, 2013

Status: Completed

Photo of Dr. Linda L. Garland

Get Help Contacting Dr. Linda L. Garland


    Privacy policy: All information is secure and will never be released

    TRUSTe

    Free

    Mesothelioma Treatment Guide

    Please fill in the form to request our FREE Mesothelioma Treatment Guide.
    It will be sent to you within 24 hours.

    Free Mesothelioma Treatment Guide



      Privacy policy: All information is secure and will never be released

      TRUSTe